Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,600,000 sq. ft., is pleased to announce that it has received conditional approval to uplist (the “Uplisting”) its common shares (the “Common Shares”) to the Toronto Stock Exchange (the “TSX”) from the TSX Venture Exchange (the “TSXV”).
“Today’s announcement represents a significant validation of the vision and hard work our entire team has poured into building Cannara. I want to thank our employees, shareholders, and partners who have supported us on this journey. We look forward to completing the final listing requirements and joining the TSX, where we believe their enhanced platform will provide additional visibility to potential new investors and greater liquidity for our shareholders as we continue to execute on our brand, growth and profitability strategy,” commented Zohar Krivorot, Founder and CEO of Cannara.
Final approval of the Uplisting is subject to the Company meeting certain conditions required by the TSX. Upon completion of the final listing requirements, the Company’s Common Shares will be delisted from the TSXV. Cannara common shares will continue to trade under the stock symbol “LOVE” upon listing on the TSX. The Company will issue a press release once the expected commencement date for trading of Cannara’s Common Shares on the TSX is confirmed.